TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025

TuHURA secures broad US patent for TBS-2025, extending protection to 2042.

What the company is saying

TuHURA Biosciences, Inc. (NASDAQ:HURA) is announcing the issuance of US Patent No. 12,760,104, which covers its VISTA-inhibiting antibody TBS-2025, including antigen-binding fragments, framework and Fc region modifications, and bispecific/multi-specific antibodies across all human antibody classes. The company emphasizes that this patent provides protection for TBS-2025 as both a single agent and in combination with various cancer therapies, as well as for use in autoimmune disease and infection. The patent term runs until February 18, 2042, prior to any extensions. Dr. James Bianco, President and CEO, frames the patent as critical for expanding into blood cancers and other indications, and as a value driver for future partnerships. The announcement highlights TuHURA’s pipeline, including the Phase 3 trial of IFx-2.0 in Merkel Cell Carcinoma and the Phase 1b trial of TBS-2025 in mut NPM1 r/r AML, which represents about 35% of AML patients. The tone is confident and forward-looking, stressing the breadth of intellectual property and the potential for expanded therapeutic applications.

What the data suggests

The patent, numbered 12,760,104, has been formally issued by the USPTO and secures broad claims for TBS-2025, including molecular variants and combination therapies. The patent term extends until February 18, 2042, providing long-term exclusivity for the asset. TBS-2025 is in a Phase 1b trial for mut NPM1 r/r AML, a subgroup comprising approximately 35% of AML patients, but no clinical data or efficacy results are disclosed. The company also has a Phase 3 trial underway for IFx-2.0 in advanced or metastatic Merkel Cell Carcinoma as an adjunct to Keytruda. The announcement is specific about the scope of patent coverage and pipeline stage, but lacks financial figures, operational metrics, or clinical outcomes. The evidence provided is strong for the patent grant and pipeline status, but all claims about future therapeutic expansion and commercial value remain unproven at this stage.

Analysis

The announcement is positive in tone, highlighting the issuance of a broad US patent for TBS-2025 and ongoing clinical trials. The patent grant is a realised milestone and is well-supported by documentary evidence. However, much of the narrative is forward-looking, emphasizing potential expansion into new indications, future collaborations, and the value of the patent for long-term opportunities. The company is still in clinical development (Phase 1b and Phase 3 trials), so any commercial or financial benefits are long-term and uncertain. There is no disclosure of revenue, profit, cash flow, or even clinical efficacy data, which is typical for a pre-commercial biotech but means the investment case rests on future potential rather than current results. The language around expanding therapeutic applications and enhancing value for future partners is aspirational and not yet substantiated by clinical or commercial outcomes. The capital intensity flag is set because late-stage clinical trials are expensive, and there is no immediate earnings impact.

Risk flags

• ●The company’s value proposition is heavily dependent on the successful clinical development and eventual approval of TBS-2025 and IFx-2.0, both of which are still in early or mid-stage trials. Failure in these trials would undermine the commercial potential of the newly issued patent.
• ●The announcement does not disclose any financial figures, cash position, or funding runway, raising questions about the company’s ability to finance expensive late-stage clinical programs through to completion.
• ●The broad therapeutic claims for TBS-2025, including autoimmune disease and infection, are not supported by clinical data in this release, making these expansion opportunities speculative and subject to significant scientific and regulatory risk.

Bottom line

TuHURA’s new US patent secures broad intellectual property protection for TBS-2025 until 2042, covering a wide range of molecular formats and therapeutic uses. This strengthens the company’s position in the immuno-oncology space and could enhance its appeal to potential partners, but the value of this patent will only be realized if TBS-2025 and other pipeline assets succeed in clinical development. With TBS-2025 in Phase 1b for a subgroup representing 35% of AML patients and IFx-2.0 in a Phase 3 trial, the company faces years of clinical and regulatory hurdles before any commercial returns are possible. The absence of financial disclosures means investors have no visibility into the company’s funding or burn rate. The key takeaway is that this is a long-term IP milestone, not a near-term revenue event; future value depends on clinical progress and eventual market entry.

Announcement summary

(NASDAQ:HURA) TuHURA Biosciences, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued Patent No. 12,760,104, titled "Anti-VISTA Antibodies and Uses Thereof." The patent provides coverage for TBS-2025, TuHURA's VISTA-inhibiting antibody, including antigen-binding fragments, modifications to the frameworks and Fc regions, and bispecific/multi-specific antibodies across all classes of human antibodies. The patent also covers the use of TBS-2025 as a single agent or in combination with radiotherapy, chemotherapy, targeted therapies, tyrosine kinase inhibitor therapies, and immune checkpoint inhibitors, including PD-1 inhibitors. Additionally, the patent claims extend to methods of treatment beyond cancer, including autoimmune disease and infection. The patent term extends to February 18, 2042, prior to any potential patent term adjustment or regulatory extension. Dr. James Bianco, President and Chief Executive Officer of TuHURA, stated that VISTA is a critical target in AML, MDS, and multiple myeloma, and that the patent protection allows the company to expand therapeutic applications and enhance the value of TBS-2025 for future collaborations. TuHURA is a Phase 3 immuno-oncology company focused on overcoming resistance to cancer immunotherapy. The company's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors and is being evaluated in a single randomized placebo-controlled Phase 3 registration trial as adjunctive therapy to Keytruda® (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. TuHURA is also developing TBS-2025 in a Phase 1b clinical trial for patients with mut NPM1 r/r AML, a subgroup representing approximately 35% of AML patients. The company is leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific, bi-functional antibody drug conjugates (ADCs) targeting Myeloid-Derived Suppressor Cells to inhibit their immune-suppressing effects and prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Disagree with this article?